NCT00720590View on ClinicalTrials.gov

Effect of the HIV Protease Inhibitors Atazanavir and Lopinavir/Ritonavir on Cardiovascular Disease Risk Factors

NACompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

November 30, 2003

Primary Completion Date

September 30, 2006

Study Completion Date

October 31, 2006

Conditions
Endothelial Dysfunction
Interventions
DRUG

Atazanavir

400 mg of atazanavir (two 200-mg capsules) per day for 4 weeks

DRUG

Lopinavir/ritonavir

400 mg/100 mg of lopinavir/ritonavir (three soft-gel capsules, each containing 133.3 mg lopinavir and 33.3 mg ritonavir) twice per day with food for 4 weeks

DRUG

Placebo

Daily dose of placebo for 4 weeks

Trial Locations (1)

46202

Indiana University School of Medicine, Indianapolis

All Listed Sponsors
collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

lead

Indiana University

OTHER

NCT00720590 - Effect of the HIV Protease Inhibitors Atazanavir and Lopinavir/Ritonavir on Cardiovascular Disease Risk Factors | Biotech Hunter | Biotech Hunter